RecruitingPhase 3NCT07444775

Lattice Radiation Therapy Versus Conventional Radiation Therapy for the Palliation of Large Tumors


Sponsor

University Health Network, Toronto

Enrollment

148 participants

Start Date

Nov 18, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this randomized, phase III trial is to to determine if Spatially Fractionated Lattice Radiotherapy (SFRT) known as LATTICE therapy, leads to a greater reduction in pain or discomfort compared with conventional Radiation Therapy (RT) in patients with large tumours. This is evaluated by assessing if a greater proportion of patients who receive RT with SFRT will have an improvement in pain/discomfort at 30 days defined using the International Consensus Pain Response (ICPR) compared with those treated with conventional RT.


Eligibility

Min Age: 18 YearsMax Age: 99 Years

Inclusion Criteria10

  • Diagnosis of solid tumor by at least one criterion below:
  • a. Pathologically or cytologically proven solid tumor greater than 5 cm (largest dimension) from a primary site or site of metastasis and unsuitable for surgical resection or definitive RT. b. HCC diagnosed by standard imaging criteria permitted: arterial enhancement and delayed washout on multiphasic computerized tomography (CT) or magnetic resonance imaging (MRI) in the setting of cirrhosis or chronic hepatitis B or C without cirrhosis
  • Eastern Cooperative Oncology Group (ECOG) Status: 0-4 within 14 days of randomization
  • In the investigator's opinion, patient requires palliative radiation therapy to a lesion >5 cm measured in one of the following ways:
  • Imaging performed within 90 days prior to randomization per Response Evaluation Criteria in Solid Tumors (RECIST)
  • CT simulation performed for radiation planning
  • Able to understand and provide written consent
  • Willing and have the ability to complete the baseline and post-treatment questionnaires (short form brief-pain inventory) and to maintain a pain diary
  • Patient is not pregnant, planning on becoming pregnant or planning on fathering a child in the next 90 days
  • Patient must be accessible for treatment and follow-up. Investigators must ensure the patients randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-up

Exclusion Criteria6

  • Prior radiotherapy that would result in substantial overlap of the irradiated volume thus precluding per protocol treatment
  • Requirement for urgent surgical intervention prior to radiation treatment
  • Confirmed pregnancy
  • Hematologic primary malignancy
  • Medical condition precluding the delivery of per protocol treatment (e.g. connective tissue disorder)
  • Tumors overlying critical CNS, heart or spinal cord compression

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONConventional Radiation Therapy

Delivered using simple techniques and includes dose prescriptions of: 8Gy in 1 fraction, 20Gy in 5 fractions, and 30Gy in 10 fractions

RADIATIONSpatially fractionated radiation therapy

LRT delivers ablative doses to discrete vertices within a tumor, forming a "lattice" while restricting the periphery of the tumor to a safe, low dose thereby minimizing radiation exposure to nearby OAR.


Locations(1)

Princess Margaret Cancer Center

Toronto, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07444775